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Abstract
Background
HIV/AIDS causes high morbidity and mortality through both immunosuppression and complications not directly related to immunosuppression. 
Haematological abnormalities, including various cytopenias, occur commonly in HIV through immune and non-immune pathways. Though these 
complications could potentially cause serious clinical implications, published literature on the magnitude of  this problem and its associated factors in 
Tanzania is scarce. This study aimed at determining the prevalence and risk factors of  HIV-associated cytopenias among ART-naive patients enrolling 
for care and treatment services at Bugando Care and Treatment Centre (CTC) in Mwanza, Tanzania.
Methods
This was a cross-sectional clinic-based study done between March 2015 and February 2016, involving all antiretroviral therapy (ART)-naive adult HIV-
positive patients enrolling for care and treatment services at Bugando CTC. Patients younger than 18 years and those with missing data were excluded. 
Data were analysed using Stata version 11 to determine the prevalence and risk factors of  cytopenias.
Results
A total of  1205 ART-naive patients were included. Median age was 41 years (interquartile range [IQR] 32 to 48). Most participants were female (n = 
789; 65.6%), with a female-to-male ratio of  2:1. The median baseline CD4 count was 200 cells/µL (IQR 113 to 439). About half  (49%) of  the study 
participants had baseline CD4 counts less than 200 cells/µL. Anaemia, leucopenia, and thrombocytopenia were found in 704 (58.4%), 285 (23.6%), and 
174 (14.4%) participants, respectively, and these were strongly associated with advanced HIV infection.
Conclusions
The magnitude of  cytopenias is high among ART-naive HIV-positive adults, and cytopenias are more marked with advanced HIV infection. Early 
diagnosis of  HIV and timely initiation of  ART could potentially reduce the number of  people living with advanced HIV disease and its associated 
complications, including the cytopenias investigated in this study. Patients with cytopenias should undergo thorough screening for tuberculosis, which 
is an important and treatable correlate of  cytopenia, in addition to close follow-up for any potential negative outcomes.
Introduction
HIV is still a global problem causing extensive morbidity and 
mortality worldwide, especially in sub-Saharan Africa, where 
more than 70% of  all HIV cases occur.1 HIV-1 is the most 
virulent form of  HIV and is responsible for most of  the 
global burden of  HIV disease.2
Morbidity and mortality in HIV/AIDS are mainly attributed 
to opportunistic infections and AIDS-defining illnesses.3 A 
considerable proportion of  the ongoing efforts to reduce 
HIV/AIDS-related morbidity and mortality is devoted to 
scaling up access to HIV care and treatment services.4 In 
2014, about 28 million people living with HIV/AIDS were 
eligible for antiviral therapy (ART); of  these, about 15.8 
million people were estimated to be receiving ART.1 The 
evidence accumulating on the effectiveness of  ART suggests 
that the use of  ART considerably improves survival of  
people living with HIV/AIDS by reducing the frequency of  
AIDS-related events.5,6
Despite these efforts and successeses, there is still a 
large burden of  HIV-related morbidity and mortality, 
notably due to complications that are not secondary to 
immunosuppression.7,8 Haematological complications 
are reported to be among the most common non-
immunosuppressive complications of  HIV. These frequently 
present as cytopenias, especially in ART-naive patients. 
These complications can have serious clinical consequences, 
including increased rate of  AIDS progression and mortality 
from anaemia,9 as well as increased risk of  bacterial 
infection10 and bleeding11 from granulocytopenia and 
thrombocytopenia, respectively. However, published data on 
the magnitude of  this problem and its associated factors are 
scarce in our setting. Therefore, the aim of  this study was to 
determine the prevalence and risk factors of  HIV-associated 
cytopenias among ART-naive adult HIV-positive patients 
enrolling for care and treatment services at Bugando Care 
and Treatment Centre in Mwanza, Tanzania.
Methods
Study design, setting, and population
This was a cross-sectional clinic-based study, carried out at 
Bugando Medical Centre (BMC), Care and Treatment Centre 
(CTC), between March 2015 and February 2016. BMC is a 
tertiary-level teaching hospital affiliated with the Catholic 
University of  Health and Allied Sciences (CUHAS) and the 
Weill Bugando School of  Medicine. It is located along the 
shores of  Lake Victoria in Mwanza, Tanzania, and caters 
for the country’s Lake and Western Zone. BMC has more 
than 900 beds and over 1000 employees. It currently serves a 
catchment population of  around 16 million people from the 
Mwanza, Geita, Simiyu, Mara, Kagera, Shinyanga, Tabora, 
and Kigoma areas. It runs both teaching and treatment 
services, taking care of  inpatients and outpatients. CTC 
activities are part of  BMC’s core and routine outpatient 
services. Currently, CTC serves more than 10,000 HIV-
positive patients, either diagnosed within the centre or 
referred from one of  the aforementioned catchment areas 
for expert management.
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to World Health Organization (WHO) haematological 
reference ranges and as used in other studies.13-15 Anaemia 
was therefore defined as Hb < 12.0 for females and Hb < 
13.0 g/dL for male subjects. Leucopenia was defined as an 
absolute WBC < 3.5 × 109/L, whereas thrombocytopenia 
was defined as an absolute Plt < 150 × 109/L. The cytopenias 
were further classified by degree of  severity as used in 
other studies. Based on this, Hb of  10.0 to 12.0 g/dL (for 
females) or 10.0 to 13.0 g/dL (for males) was considered 
mild anaemia, while moderate anaemia was defined as Hb 
between 8.0 and 10.0 g/dL for both sexes, and Hb < 8.0 
g/L was considered severe anaemia.16,17 Mild, moderate, and 
severe thrombocytopenia were defined as Plt of  100 to 150 
× 109/L, 50 to 100 × 109/L, and < 50 × 109/L, respectively.18 
Mild, moderate, and severe leucopenia were defined as an 
absolute WBC of  3.0 to 3.5 × 109/L, 2.0 to 3.0 × 109/L, and 
< 2.0 × 109/L, respectively.19 Advanced HIV was defined as 
CD4 count < 200 cells/µL or presentation with a WHO stage 
3 or 4 clinical event.20 Continuous variables were expressed 
as medians with interquartile ranges (IQRs) and categorical 
variables were expressed as proportions and percentages. 
The effect of  different risk factors on the odds of  having 
HIV-associated cytopenias was investigated. A univariate 
logistic regression model followed by a multivariate logistic 
regression model was used to calculate odds ratios (ORs) 
and 95% confidence intervals to quantify the strength of  
association between HIV-associated cytopenias and their 
potential predictors. In all of  our analyses, factors were 
considered significantly associated with the outcome variable 
when the P-value was ≤ 0.05. 
Ethical considerations
Permission to conduct and publish the information from 
this study was obtained from the Joint CUHAS–BMC 
Research & Ethics Committee. Written informed consent 
was obtained from all study participants. To maintain 
confidentiality, patient identifiers were not recorded. The 
results from this study will be of  benefit for both teaching 
purposes and optimisation of  patient care in our setting.
Results
General demographic, clinical, and laboratory 
characteristics of study participants
In this study, a total of  1205 ART-naive patients were 
included, with a median age of  41 years (IQR 32-48). Most 
participants were female (n = 789; 65.6%), with a female-
to-male ratio of  2:1. The majority (n = 697; 57.8%) were 
classified as having WHO clinical stage 1 or 2 disease, and 
the median baseline CD4 count was 200 cells/µL (IQR 113 
to 439). About half  (49%) of  the study participants had 
baseline CD4 counts were less than 200 cells/µL, and 21% 
had CD4 counts above 500 cells/µL. The median baseline 
Hb was 11.3 g/dL (IQR 9.5 to 13.0), whereas the median 
WBC and Plt values were 4.82 × 109/L (IQR 3.6 to 6.2) and 
240 × 109/L (IQR 182 to 309), respectively (Table 1a). Of  
the patients who presented with WHO clinical stage 1 or 2 
HIV disease, most were diagnosed to have dermatological 
conditions, with pruritic papular eruption (PPE) being the 
most common diagnosis (n = 348; 28.9%), followed by 
herpetic eruptions (n = 172; 14.3%). On the other hand, 
among those who presented with WHO clinical stage 3 or 4 
disease, tuberculosis (TB) was the commonest diagnosis (n 
= 425; 35.3%), followed by gastrointestinal candidiasis (n = 
87; 7.2%), as summarised in Figure 1.
All adult ART-naive HIV-positive patients at Bugando CTC 
were eligible for this study. Patients younger than 18 years 
and those with missing lab result details were excluded. 
A minimum sample size of  384 was calculated from the 
prevalence studies’ formula by Leslie and Kish, assuming 
a cytopenia prevalence of  50% among ART-naive HIV-
positive adults.9,12 Consenting patients were sequentially 
enrolled until the sample size was reached. Pertinent patient 
data were recorded, including age, sex, opportunistic diseases 
present at the time of  diagnosis, WHO clinical stage, 
baseline CD4 count, and most recent CD4 count. From the 
full blood count (FBC) the following values were recored: 
absolute red blood cell count (RBC), white blood cell count 
(WBC), platelet count (Plt), haemgolobin level (Hb), and red 
blood cell indices.
Blood sample collection and processing
Five millilitres of  whole blood was collected by venepuncture 
in Vacutainer tubes containing EDTA (Becton, Dickinson 
and Company, Franklin Lakes, NJ, USA) for FBC and 
CD4 count estimation. The samples were sent to BMC 
main laboratory within 2 hours for analysis. The FBC 
values were determined using a CELL-DYN 1800 (Abbott 
Laboratories, Diagnostics Division, Santa Clara, CA, USA) 
automated blood analyser, and the absolute CD4 counts 
were determined using the BD FACSCount system (Becton, 
Dickinson and Company, Franklin Lakes, NJ, USA).
Statistical analysis
Data were analysed using EpiData version 3.1 (The 
EpiData Association, Odense, Denmark) and Stata version 
11 (StataCorp, College Station, TX, USA). In this study 
haematological abnormalities were defined according 
Table 1: General demographic, clinical, and laboratory characteristics of 
1205 ART-naive HIV-positive adults
Characteristics Frequency Percentage Median (IQR)
Demographic variables
Age group (years)
≥ 40 Years 611 50.7 -
< 40 Years 594 49.39 -
Median (IQR) age (years) - - 41 (32-48)
Sex
Male 416 34.4 -
Female 789 65.6 -
WHO clinical stage of HIV 
disease
Stage 1 & 2 697 57.8 -
Stage 3 & 4 508 42.2 -
Baseline CD4 count (cells/µL)
< 200 594 49.3 -
200 to 350 260 21.6 -
351 to 500 97 8.1 -
> 500 254       21.1 -
Median (IQR) laboratory 
values




White blood cell count 
(x109/L)
- - 4.82 (3.6-6.2)
Platelet count (x109/L) - - 240 (182-309)
IQR = interquartile range; WHO = World Health Organization
Table 1: General demographic, clinical, and laboratory 
characteristics of 1205 ART-naive HIV-positive adults
MMJ VOL 29 (1): March 2017
Cytopenias among ART-naive patients with advanced HIV   45Malawi Medical Journal 29 (1): March 2017
http://dx.doi.org/10.4314/mmj.v29i1.9
The prevalence of cytopenias and their potential 
risk factors 
A total of  704 (58.4%) of  the study participants were found 
to have anaemia, whereas leucopenia and thrombocytopenia 
were found in 285 (23.7%) and 174 (14.4%) of  the participants, 
respectively. Bicytopenia occurred in at least 88 (7.30%) of  
the participants, with anaemia and leucopenia being the 
most common combination (n = 193; 16.0%). Pancytopenia 
occurred in 61 (5.1%) of  the studied patients (Figure 2). By 
severity, 148 (12.2%) of  the study participants had severe 
anaemia, whereas severe leucopenia and thrombocytopenia 
were observed in 15 (1.2%) and 16 (1.3%) of  the studied 
patients, respectively (Table 2). Anaemia commonly occurred 
among patients with WHO clinical stage 3 and 4 disease (48.3% 
and 33.5%, P < 0.001), and among those with baseline CD4 
counts less than 200 cells/µL (OR = 1.3, P < 0.020). While 
tuberculosis was the commonest opportunistic condition, 
the odds of  having anaemia were significantly associated 
with a pulmonary tuberculosis (PTB) diagnosis (OR = 1.5, 
P = 0.01) and disseminated tuberculosis (DTB) (OR = 2.7, 
P < 0.001). Using a multivariate regression model, anaemia 
was independently associated with WHO clinical stage 3 or 
4 HIV disease (OR = 1.5, P = 0.016), CD4 counts < 200 
cells/µL (OR = 1.3, P = 0.04), and DTB (OR = 2.1, P = 
0.019), as summarised in Table 3.
Table 4 shows that leucopenia was strongly predicted by a 
female gender (OR = 1.5, P = 0.006) in addition to HIV 
WHO clinical stage 3 or 4 (OR = 1.8, P < 0.001), PTB (OR 
= 1.5, P = 0.016), DTB (OR = 2.0, P = 0.003) and baseline 
CD4 of  less than 200 cells/µL (OR = 2.8, P <0.001). 
Using a multivariate model (see Table 4), leucopenia was 
independently associated with a female gender (OR = 1.5, 
P = 0.009), CD4 count less than 200/µL (OR = 2.8, P < 
0.001), and DTB (OR = 1.8, P = 0.04).
Thrombocytopenia was strongly predicted also by WHO 
clinical stage 3 or 4 disease (OR = 1.9, P < 0.001), baseline 
CD4 less than 200 cells/µL (OR = 1.6, P = 0.003), and 
DTB (OR = 2.5, P <0.001); all of  these factors remained 
as independent risk factors for thrombocytopenia on a 
multivariate model, as summarised in Table 5.
Table 2: Distribution of cytopenias by severity among 1205 ART-naive HIV-positive adults
Severity level Anaemia Leucopenia Thrombocytopenia
Mild cytopenias
Range Hb (10.0 to 12.0  or 
13.0♂ g/dL)
WBC (3.0 to 3.5 x109/L) Plt (100 to 150 x109/L)
Frequency (%) 352 (29.2%) 133 (11.0%) 134 (11.1%)
Moderate cytopenias
Range Hb (8.0 to10.0 g/dL) WBC (2.0 to 3.0 x109/L) Plt (50 to 100 x109/L)
Frequency (%) 204 (16.9) 137 (11.4%) 24 (2.0%)
Severe cytopenias
Range Hb (< 8.0g/dL) WBC (< 2.0 x109/L) Plt (< 50 x109/L)
Frequency (%) 148 (12.2%) 15 (1.2%) 16 (1.3%)
Hb = haemoglobin concentration (note slightly different ranges used for females  and males♂); Plt = platelet count; 























Figure 1: Opportunistic illness diagnoses among 1205 ART-naive HIV-positive adults 
PPE = pruritic papular eruption; PTB = pulmonary tuberculosis; HZ = herpes zoster; PGL = persistent 
generalised lymphadenopathy; EPTB = extrapulmonary tuberculosis; ORCA = oral candidiasis; BPNA = 
recurrent bacterial pneumonia; CDIA = chronic diarrhoea; OESCA = oesophageal candidiasis; PCP = 
Pneumocystis jirovecii pneumoniai tion of cytopenias by severity among 1205 ART-naive HIV-positive adults
Figure 1: Opportunistic illness diagnoses among 1205 ART-naive HIV-positive adults
PPE = pruritic papular eruption; PTB = pul onary tuberculosis;  = herpes zoster; P L = persistent generalised 
lymphadenopathy; EPTB = extrapulmonary tuberculosis; ORCA = oral candidiasis; BPNA = recurrent bacterial 
pneumonia; CDIA = chronic diarrhoea; OESCA = oesophageal candidiasis; PCP = Pneumocystis jirovecii pneumonia
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(Hb < 12.0♀ or 13.0♂ g/dL) Unadjusted  
OR (95% CI)
P-value Adjusted  
OR (95% CI)
P-value
No (%) Yes (%)
Age group
≥ 40 years 247 (49.3) 364 (51.7) - - - -
< 40 years 254 (50.7) 340 (48.3) 1.1 (0.9 to 1.4) 0.41 - -
Sex
Female 334 (66.7) 455 ( 64.6) - - - -
Male 167 (33.3) 249 (35.4) 0.9 (0.7 to 1.2) 0.46 - -
WHO clinical HIV stage
Stage 1 & 2 333 (66.5)   364 (51.7) 1.9 (1.5 to 2.3) < 0.001 1.5 (1.1 to 2.2) 0.016
Stage 3 & 4 168 (33.5) 340 (48.3) - - - -
Baseline CD4 count 
(cells/µL)
< 200 227 (45.3) 367 (52.2) - - - -




eruptions 158 (31.5) 190 (27.0) 0.8 (0.6 to 1.0) 0.10 - -
Pulmonary 
tuberculosis 914 (18.2) 172 (24.4) 1.5 (1.1 to 1.9) 0.010     1.1 (0.7 to 1.7) 0.60
Herpes zoster 82 (16.4) 90 (12.8) 0.7 (0.5 to 1.0) 0.080     - -
Persistent generalised 
lymphadenopathy 71 (14.2) 74 (10.5)   0.7 (0.5 to 1.0) 0.055 - -
Extrapulmonary 
tuberculosis 33 (06.6) 66 (09.4) 1.5 (0.9 to 2.3) 0.084     - -
Disseminated 
tuberculosis 19 (03.8) 67 (09.5) 2.7 (1.6 to 4.5) < 0.001 2.1 (1.1 to 3.7) 0.019
Oral candidiasis 29 (05.8) 44 (06.3) 1.1 (0.7 to 1.8) 0.33 - -
Bacterial pneumonia 8 (01.6) 22 (03.1) 2.0 (0.9to 4.5) 0.099     - -
Hb = haemoglobin concentration; ♀ = female; ♂ = male; OR = odds ratio; CI = confidence interval; WHO = World Health Organization
Figure 2: Distribution of cytopenias among 1205 ART-naive HIV-positive adults 
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               38 (3.2%)  65 (5.4%)  
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(WBC < 3.5 x 109/L) Unadjusted  
OR (95% CI)
P-value Adjusted  
OR (95% CI)
P-value
No (%) Yes (%)
Age group
≥ 40 years 467 (50.8) 144 (50.5) - - - -
< 40 years 453 (49.2) 141 (49.5) 1.0 (0.7 to 1.3) 0.95 - -
Sex
Female 336 (36.6) 78 (27.4) - - - -
Male 582 (63.4) 207 (72.6) 1.5 (1.1 to 2.0) 0.006     1.5 (1.1 to 2.0) 0.009    
WHO clinical HIV stage
Stage 1 & 2 563 (61.2) 134 (47.1) 1.8 (1.3 to 2.3) < 0.001 1.3 (0.9 to 2.0) 0.17
Stage 3 & 4 357 (38.8) 151 (52.9) - - - -
Baseline CD4 count 
(cells/µL)
< 200 399 (43.4) 195 (68.4) - - - -




eruptions 271 (29.5) 76 (26.6) 0.9 (0.6 to 1.2) 0.36 - -
Pulmonary 
tuberculosis 186 (20.2) 77 (27.0) 1.5 (1.1 to 2.0) 0.016     1.3 (0.8 to 2.0) 0.29
Herpes zoster 146 (15.9) 26 (09.1)  0.5 (0.3 to 0.8) 0.005     - -
Persistent generalised 
lymphadenopathy 119 (12.9) 26 (09.1) - - - -
Extrapulmonary 
tuberculosis 77 (8.4) 22 (07.7) 0.9 (0.6 to 1.5) 0.73 - -
Disseminated 
tuberculosis 54 (5.9) 32 (11.2) 2.0 (1.2 to 3.2) 0.003 1.8 (1.0 to 3.2) 0.042
Oral candidiasis 48 (5.2) 25 (08.8) 1.7 (0.8 to 3.8) 0.17 - -
Bacterial pneumonia 20 (2.2) 10 (03.5) 1.6 (0.8 to 3.5) 0.21 - -
WBC = white blood cell count; OR = odds ratio; CI = confidence interval; WHO = World Health Organization
Table 6 summarises the 
univariate and multivariate 
analyses for factors 
associated with multiple 
cytopenias. Patients who had 
multiple cytopenias were 
likely to be female (OR = 1.4, 
P = 0.05), in  WHO clinical 
stage 3 or 4 (OR = 2.1, P < 
0.001), with  baseline CD4 
counts less than 200 cells/
µL (OR = 3.2, P < 0.001), 
and those diagnosed to have 
PTB (OR = 1.5, P = 0.015), 
DTB (OR=2.5, P < 0.001), 
and recurrent bacterial 
pneumonia (OR = 2.3, P 
= 0.04). On a multivariate 
logistic regression model, 
multiple cytopenias remained 
independently predicted by 
CD4 counts less than 200 
cells/µL (OR = 3.1, P < 
0.001), and DTB (OR = 2.5, 
P = 0.012). The strength of  
association of  other factors 
with multiple cytopenias was 
not statistically significant.
Discussion
The objective of  this 
study was to determine 
the prevalence and risk 
factors of  HIV-associated 
cytopenias. Anaemia was 
found to be the most 
frequent HIV-associated 
cytopenia, occurring in 
704 (58.4%) of  the study 
thrombocytopenia in 26.8% and 16.1% of  ART-naive 
patients, respectively, in a Nigerian population.29 Earlier 
studies indicated that platelet counts of  less than 150 were 
more common among ART-naive patients, with prevalence 
figures ranging between 6% and 30% in most studies.12,27,30
Evidence from available studies has shown that patients 
with anaemia have reduced survival time and accelerated 
HIV disease progression. For instance, an earlier study in 
developed countries by Mocroft et al. indicated that, at 12 
months, HIV patients with mild anaemia had a significantly 
lower survival rate than those without anaemia (84.1% vs. 
96.9%), and that prognosis and survival time was even 
worse among severely anemic patients.31 Similarly, in the 
USA, Sullivan and colleagues found that survival rate was 
considerably reduced among anaemic HIV patients, with a 
relative risk of  death of  148%.8 Another study in Tanzania 
by O’Brien et al. showed that anaemia is an independent risk 
factor for mortality and disease progression among HIV-
positive women.32 In this study patients with anaemia had 
increased risk of  mortality, with a hazard ratio (HR) of  2.06 
for mild anaemia, 2.7 for moderate anaemia, and 3.19 for 
severe anaemia.
Despite the high frequency of  cytopenias in other cell 
lines, clinical implications and specific treatments are not 
well described. Available studies from developed countries 
 : nivariate and mult variate analysis f  f ctors associat d with leuc penia among 1205 
ART-naive HIV-positive adults
participants, followed by leucopenia and thrombocytopenia, 
which were found in 285 (23.7%) and 174 (14.4%) of  the 
participants, respectively. In previous studies, anaemia has 
been reported in more than 60% of  patients.9,14 Compared 
to our study, lower anaemia prevalences have been reported 
in India (22%),21 Ethiopia (35%),22 Uganda (47.8%),23 and 
Nigeria (57.5%).24 On the other hand, our study reports a 
lower anaemia prevalance than several other studies that 
investigated anaemia prevalence among ART-naive patients. 
In a study from India, by Byomakesh et al., anaemia was 
found in 65.5% of  the study participants,14 while a prior 
study in rural Tanzania by Johannessen et al. in 2011 reported 
a prevalence of  77.4% among ART-naive HIV-positive 
adults.25 Daka et al. reported an anaemia prevalence of  86.5% 
among ART-naive HIV positive patients in Ethiopia.26
Among a number of  studies that have reported on HIV-
associated cytopenias involving other cell lines, results have 
been consistently comparable to our findings. Leucopenia is 
also common in ART-naive patients, with a prevalence that 
ranges between 10% and 44%.12,27 A study from northern 
Ethiopia indicated that 16.6% of  ART-naive patients 
had leucopenia, while 9.0% had thrombocytopenia.28 In 
Uganda, leucopenia and thrombocytopenia were reported 
in 24.3% and 8.3% of  the study participants, respectively.23 
Akinsegun et al., in a 2010 study, reported leucopenia and 
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(Plt < 1.5 x 109/L) Unadjusted  
OR (95% CI)
P-value Adjusted  
OR (95% CI)
P-value
No (%) Yes (%)
Age group
≥ 40 years 530 (51.4) 081 (46.6) - - - -
< 40 years 501 (48.6) 093 (53.4) 0.8 (0.6 to 1.1) 0.24 - -
Sex
Female 672 (65.2) 117 (67.2) - - - -
Male 359 (34.8) 57(32.8) 1.1 (0.8 to 1.5) 0.60 - -
WHO clinical HIV stage
Stage 1 & 2 619 (60.1) 78 (44.8) 1.9 (1.3 to 2.6) < 0.001 1.6 (1.1 to 2.2) 0.010
Stage 3 & 4 412 (39.9) 96 (55.2) - - - -
Baseline CD4 count 
(cells/µL)
< 200 490 (47.5) 104 (59.8) - - - -




eruptions 313 (30.4) 34 (19.5) 0.6 (0.4-0.8) 0.004 - -
Pulmonary 
tuberculosis 216 (21.0) 47 (27.0) 1.4 (1.0 to 2.0) 0.074 - -
Herpes zoster 151 (14.7) 21 (12.1) 0.8 (0.5 to 1.3) 0.37 - -
Persistent generalised 
lymphadenopathy 126 (12.2) 19 (10.9) 0.9 (0.5 to 1.5) 0.63 - -
Extrapulmonary 
tuberculosis 94 (9.1) 5 (2.9) 0.3 (0.1 to 0.7) 0.009 - -
Disseminated 
tuberculosis 62 (0 6.0) 24 (13.8) 2.5 (1.5 to 4.1) < 0.001 1.9 (1.1 to 3.2) 0.022
Oral candidiasis 59 (05.7) 14 (8.1) 1.4 (0.8 to 2.6) 0.24 - -
Bacterial pneumonia 22 (2.1)3 8 (4.6) 2.2 (1.0 to 5.0) 0.060 - -
Plt = platelet count; OR = odds ratio; CI = confidence interval; WHO = World Health Organization
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le 5: Univariate and multivariate analysis f r factors associated with thrombocytopenia amo g 
1205 ART-naive HIV-positive adults
Figure 3: Cytopenia type by CD4 count a ong 1205 ART-naive HIV-positive patients
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anaemia was reduced from 57.5% pre-ART to 24.3% post-
ART, while leucopenia and thrombocytopenia were reduced 
from 6.1% and 9.6% to 1.7% and 1.2%, respectively.24 An 
important observation from available studies is that even 
with this great effect of  ART on HIV-associated cytopenias, 
the reversal of  these complications is usually incomplete. 
This suggests that the mechanisms underlying HIV-
associated cytopenias are complex and can only be reversed 
partially with the use of  ART. Among other mechanisms, 
studies suggest reduced marrow activity in the production 
of  different cell lines, which can be due to HIV itself, 
opportunistic infections, or cytokine-mediated changes,36,37 
with a tendency for the effects of  these mechanisms to 
increase in magnitude with worsening HIV disease. For 
example, regarding anaemia, studies illustrate that among 
asymptomatic HIV-positive patients, anaemia occurs in 8% 
to 18% of  patients, as compared to 20% to 50% of  patients 
with intermediate disease progression, and 70% to 75% 
of  patients with advanced HIV.38,39 In an Ethiopian study, 
where 29.7%, 16.6%, and 9% of  ART-naive patients had 
anaemia, leucopenia, and thrombocytopenia, respectively, 
it was indicated that at CD4 counts greater than 350 cells/
µL, only 18.8%, 15.3%, and 3.5% of  these patients had 
anaemia, leucopenia, and thrombocytopenia respectively. 
Comparatively, at CD4 counts  less than 200 cells/µL, it was 
indicated that there was a much higher rate of  cytopenias 
with anaemia, leucopenia, and thrombocytopenia being 
reported in 34.5%, 43.1%, and 15.5% of  the ART-naive 
patients with cytopenias.28 Another study in Nigeria by 
Akinsegun et al., studying haematological abnormalities 
in ART-naive patients, demonstrated that at CD4 counts 
above 500 cells/µL, anaemia occurred in only 5.26% of  the 
study participants, while leucopenia and thrombocytopenia 
were found in 10.5% and 13.15% of  the study participants, 
respectively. Conversely, at a CD4 count of  less than 200 
cells/µL, anaemia was present in between 50% and 71% 
of  study participants, whereas leucopenia occurred in 55% 
to 75% of  participants, and thrombocytopenia in 15% to 
53.3%.29 These observations are also supported by our finding 
that among those patients with anaemia, 8.2%, 22.6%, and 
52.1% had mild, moderate, and severe immunosuppression. 
Additionally, in the current study it was noted that at CD4 
counts above 500 cells/µL, only 17.0%, 8.4%, and 17.8% 
of  patients had anaemia, leucopenia, and thrombocytopenia, 
respectively, compared to 52.1%, 68.4%, and 59.8% at CD4 
counts less than 200 cells/µL (Figure 3).
In our study, patients with WHO clinical stage 3 or 4 disease 
were 1.8 times more likely to have anaemia and leucocytopenia 
and 1.9 times more likely to have thrombocytopenia. 
Additionally they were 2.1 and 2.7 times more likely to have 
bicytopenia and pancytopenia than patients with WHO 
clinical stage 1 or 2 disease. Patients with baseline CD4 
counts less than 200 cells/µL were 1.4 to 2.8 times more 
likely to have anaemia, thrombocytopenia, and leucopenia. 
Table 6: Univariate and multivariate analysis for factors associated with multiple cytopenias among 1205 ART-
naive HIV-positive adults
Variable
Multicytopenia Unadjusted  
OR (95% CI) P-value
Adjusted  
OR (95% CI) P-valueNo (%) Yes (%)
Age group
≥ 40 years 507 (50.1) 104 (53.9) - - - -
< 40 years 505 (49.9) 089 (46.1) 1.2 (0.8 to 1.6) 0.34 - -
Sex
Female 651 (64.3) 138 (71.5) - - - -
Male 361 (35.7)  55 (28.5) 1.4 (1.0 to 1.9) 0.050 1.4 (1.0 to 2.0) 0.067
WHO clinical HIV stage
Stage 1 & 2 615 (60.8) 82 (42.5) 2.1 (1.5 to 2.9) < 0.001 1.3 (0.8 to 2.2) 0.24
Stage 3 & 4 397 (39.2) 111 (57.5) - - - -
Baseline CD4 count 
(cells/µL)
< 200 455 (45.0) 139 (72.0) - - - -




eruptions 299 (29.6) 48 (24.9) 0.8 (0.6 to 1.1) 0.19 - -
Pulmonary 
tuberculosis 208 (20.6) 55 (28.5) 1.5 (1.1 to 2.2) 0.015 1.4 (0.8 to 2.4) 0.19
Herpes zoster 157 (15.5) 15 (7.8) 0.5 (0.3 to 0.8) 0.006 - -
Persistent generalised 
lymphadenopathy 125 (12.4) 20 (10.4) 0.8 (0.5 to 1.4) 0.44 - -
Extrapulmonary 
tuberculosis 86 (8.5) 13 (6.7) 0.8 (0.4 to 1.4) 0.42 - -
Disseminated 
tuberculosis 60 (5.9) 26 (13.5) 2.5 (1.5 to 4.0) < 0.001 2.3 (1.2 to 4.3) 0.012     
Oral candidiasis 58 (05.7) 15 (07.8) 1.4 (0.8 to 2.5) 0.28 - -
Bacterial pneumonia 21 (02.1) 9 (4.7) 2.3 (1.0 to 5.1) 0.040 2.1 (0.8 to 5.0) 0.11
OR = odds ratio; CI = confidence interval; WHO = World Health Organization
indicate that a reduction in 
absolute white blood cell 
count has been associated 
with increased risk of  
severe bacterial infection 
and hospitalisation,10 
and that patients with 
thrombocytopenia have a 
high potential for bleeding.11 
However, with a lack of  
comparable studies from 
Africa, these findings are 
difficult to generalise to the 
African region. Initiation 
of  ART has generally been 
regarded as the standard 
management for HIV/AIDS 
patients. In addition to the 
restoration of  immunological 
function, ART has also been 
shown to improve HIV-
related cytopenias, especially 
anaemia.25,33,34 A study by 
Johannessen et al. recorded 
a reduction of  anaemia from 
77.4% among ART-naive 
patients to 38.2% after 12 
months of  ART.25 A study 
in Nigeria demonstrated 
a reduction in anaemia 
prevalence from 69.17% 
to 51.15% after ART.35 
Another study in Nigeria, by 
Denue et al., also showed a 
significant improvement of  
haematological parameters 
with ART: the prevalence of  
le 6: Univariate and multivariate analysis f r factors associated with multiple cytopenias 
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HIV-associated cytopenias represent an ongoing challenge 
because of  the variety of  potential aetiologies, which are in 
most cases difficult to adequately investigate and treat. For 
example, anaemia is the commonest form of  HIV-associated 
cytopenia and has frequently been associated with several 
factors that may either cause reduced bone marrow activity, 
chronic blood loss, or peripheral red blood cell destruction.40 
Reduced bone marrow activity frequently follows (1) 
marrow infiltrative diseases like opportunistic infections 
and malignances,41 (2) inadequate marrow stimulation (for 
example, from reduced erythropoietin production),42 (3) 
bone marrow suppression (from medications like zidovudine 
[AZT] and cotrimoxazole [CTX] or from the suppressive 
effects of  soluble proteins from HIV and cytokines),43,44 
(4) nutritional deficiencies with reduced raw material supply 
(iron, folate, and vitamin B12),45,46 among others. In HIV 
patients, chronic blood loss is a potential cause of  anaemia—
commonly from gastrointestinal lesions like Kaposi’s 
sarcoma, oral and oesophageal candidiasis, cytomegalovirus, 
oesophagitis, or colitis, and from hookworm infestations.40 
Haemolytic anaemia in HIV-positive patients usually follows 
autoimmune reaction (autoimmune haemolytic anaemia, 
AIHA), and though less frequent, patients with AIHA may 
potentially react to blood transfusion when this cause of  
anaemia is not ruled out.47
Thrombocytopenia in HIV patients has been shown to 
be a frequent complication among cirrhotic patients with 
associated portal hypertension, where it occurs in more than 
50% of  this subgroup of  patients.48,49 Reduced production 
of  thrombopoetin, splenic sequestration, and platelet 
autoantibodies developing following hepatitis C infection, 
among others, form a list of  possible mechanisms for 
thrombocytopenia among cirrhotic patients.50,51 A number 
of  drugs have also been implicated to cause drug-induced 
thrombocytopenia (DITP), including trimethoprim, quinine, 
nonsteroidal antiinflammatory drugs (NSAIDs), and 
anticonvulsants.52,53 Furthermore, thrombocytopenia has 
been reported in more than 30% of  patients with sepsis. 
In these patients, thrombocytopenia is usually associated 
with disseminated intravascular coagulation (DIC), with 
increased platelet destruction.54 The thrombocytopenia in 
sepsis results partly from an associated nonimmune platelet 
destruction and bone marrow suppression with severity 
of  thrombocytopenia correlating closely to severity of  
sepsis.55 HIV-associated thrombotic thrombocytopenic 
purpura (TTP) is an important cause of  thrombocytopenia, 
first described in 1987.56 HIV is presumed to precipitate 
TTP through direct endothelial damage, which in turn 
causes local generation of  thrombin and consumption of  
metaloprotease,57 and it commonly occurs in patients with 
advanced HIV disease.58 TTP is usually characterised by 
microvascular platelet deposition and thrombus formation 
in selected organs with eventually thrombocytopenia, fever 
and haemolytic anaemia, neurological and renal dysfunction, 
among others.59
In HIV patients, the causes of  leucopenia include (1) reduced 
bone marrow activity from infiltrative conditions, marrow 
toxicity, and nutritional deficiency; (2) increased apoptosis; 
(3) HIV infection itself; (4) tuberculous marrow infiltrate; 
and (5) neoplastic infiltrates.60-62 On the other hand, most 
drugs which are currently useful in HIV, such as CTX, AZT, 
and gancyclovir are myelotoxic,63 and they can potentially 
cause neutropenia. HIV antibodies against gp120 form 
another mechanism which leads to suppression of  marrow 
progenitors.64 Leucopenia could also follow nutritional 
deficiency of  Vitamin B12,62 and a shortened neutrophil 
lifespan from accelerated apoptosis in HIV.65
With regards to opportunistic diseases present at the time of  
diagnosis in our study, TB was the most common diagnosis, 
and it was strongly associated with all forms of  cytopenia, 
especially the disseminated form of  TB, which was as an 
independent risk factor for cytopenias. This supports the 
understanding that TB is one of  the marrow infiltrative 
diseases that can potentially lead to reduced production of  
all cell lines. These findings are in agreement with several 
other studies. A prior study from Muhimbili had shown that 
patients with anaemia were 3 times more likely to have TB 
than patients without anaemia.66 Studies from elsewhere 
have also indicated that the prevalence of  TB among 
anaemic HIV patients is high especially among patients with 
severe anaemia. A study from South Africa by Kerkhoff  
et al., assessing the prevalence of  TB among HIV anaemic 
patients, indicated that TB was diagnosed in only 8.8% of  
non-anemic HIV patients, compared to 16.5%, 26.0%, and 
40.0% among those with mild, moderate, and severe anaemia, 
respectively.67 In an earlier study from the USA studying 76 
bone marrow samples among patients with cytopenias, 55 
samples (72%) were positive for TB.68 Additionally, a study 
from India indicated that TB was a common bone marrow 
infection among patients with anaemia, leucopenia, and 
thrombocytopenia.69 These findings are clinically important, 
especially in resource-limited settings where HIV and TB 
burden are highest, such that TB represents an important 
reversible cause of  cytopenia and should routinely be 
suspected among HIV patients presenting with cytopenia. 
Study limitations
This study had a number of  limitations. This was a single 
centre, and it was a hospital-based study, therefore the 
findings may not necessarily be generalisable. Since this was 
a cross-sectional study, there was no follow up, and hence 
a longitudinal study is recommended to answer questions 
related to outcomes.
Conclusions
HIV-associated cytopenias are common and tend to increase 
in magnitude and severity with worsening HIV disease. 
These findings also suggest that efforts to diagnose HIV 
at earlier stages might serve as an important strategy in the 
reduction of  most cytopenias in this subgroup of  patients. 
Earlier diagnosis may lead to earlier ART initiation and 
improved outcomes. Furthermore, patients with advanced 
HIV should be given special attention, as they are more likely 
to be affected by cytopenias, which may only partially resolve 
with ART. Tuberculosis, in particular, should be ruled out 
often, as it is a treatable cause of  the cytopenias commonly 
seen in HIV-positive patients.
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